Surgical Outcomes in Rare Movement Disorders: A Report of Seventeen Patients from India and Review of Literature

DEBJYOTI DHAR
VIKRAM VENKAPPAYYA HOLLA
NITISH KAMBLE
RAVI YADAV
DWARAKANATH SRINIVAS
PRAMOD KUMAR PAL

ABSTRACT

Background: Rare movement disorders (RMDs) throw remarkable challenges to their appropriate management particularly when they are medically refractory. We studied the outcome of functional neurosurgery among patients with RMDs.

Methods: Retrospective chart-review from 2006 to 2021 of patients with RMDs who underwent either Deep brain Stimulation (DBS) or lesional surgeries in the department of Neurology and Neurosurgery at a tertiary care centre.

Results: Seventeen patients were included. Generalized dystonia (11 patients, 64.7%) and tremor (5 patients, 29.4%) were the most common indication for surgery whereas, Wilson’s disease (8 patients, 47.1%) and Neurodegeneration with brain iron accumulation (5 patients, 29.4%) were the most common aetiology. Sixteen patients (94.1%) had objective clinical improvement. Significant improvement was noted in the dystonia motor scores both at 6-months and 12-months follow-up (n = 11, p-value of <0.01 and 0.01 respectively). Comparison between DBS and lesional surgery showed no significant difference in the outcomes (p = 0.95 at 6-months and p = 0.53 at 12-months), with slight worsening of scores in the DBS arm at 12-months. Among five patients of refractory tremor with Wilson’s disease, there was remarkable improvement in the tremor scores by 85.0 ± 7.8% at the last follow-up. Speech impairment was the main complication observed with most of the other adverse events either transient or reversible.

Discussion: Surgical options should be contemplated among patients with disabling medically refractory RMDs irrespective of the aetiology. Key to success lies in appropriate patient selection. In situations when DBS is not feasible, lesional surgeries can offer an excellent alternative with comparable efficacy and safety.
INTRODUCTION

Rare diseases (RD) are defined as those with a prevalence of less 200,000 people in United States [1]. On the contrary, the European Union under the jurisdiction of the European Medical Agency considers RDs as prevalence of less than or equal to 50 people per 100,000 population. As of now, 6000 to 8000 rare diseases have been discovered so far which has been estimated to affect 6–8% of the global population [1]. Collectively, they add up to significant burden of disease in the overall population. RDs pose remarkable challenges to the formulation of management strategies. Many of them are life-threatening or disabling which raises ethical concerns with regards to the conduct of controlled or randomised clinical trials. Thus, in most of these situations, treatment decisions are guided by evidence-limited medicine and principles of good clinical practice.

As per European Reference Network (ERN) for rare neurologic disorders (RND), neurologic manifestations are widely prevalent among RDs [2]. Movement disorders constitute one of the most important phenotypes in rare neurological disorders [2], treatment of which is often challenging with definite medical therapy available in only a handful of conditions. Often, the associated movement disorder responds unsatisfactorily to the standard medical management [3]. Since the definitive therapies for majority of the RMDs are still lacking, symptomatic management by means of surgical interventions in these often disabling and intractable movement disorders can play an immense role in improving the quality of living. With the refinement of surgical techniques, the past few decades have witnessed a significant upsurge in the role of surgical interventions as a part of treatment protocol in medically refractory movement disorders of various aetiologies. The evolution of Deep Brain Stimulation (DBS) technology has led to a decline in the number of publications related to ablative surgeries in recent times because of several advantages in the former such as reversibility, programmability, and bilateral targeting ability. Studies have also shown persistent beneficial effects of bilateral GPi DBS in patients with dystonia in long-term follow-up [4, 5]. Younger age at surgery, higher BFMDRS motor and disability scores were associated with better clinical response to DBS [4]. GPi stimulation were associated with a greater clinical benefit compared to posterior ventro-lateral (VLp) thalamic stimulation [6]. The reversibility of DBS and its modulatory effects on neural plasticity in patients with dystonia after prolonged stimulation has been robustly demonstrated by means of transcranial magnetic stimulation [7]. Experience of DBS in Parkinson’s disease has shown the large economic burden of DBS. However, in the long run, it successfully reduces the financial burden of pharmacotherapy and indirectly the social costs by improving the quality of life [8]. Robust cost-effectiveness studies of DBS in movement disorders are still lacking, and remains an area of further research [9]. There has been significant improvement of health-related quality of life (HRQoL) in patients with dystonia post-DBS, particularly with primary dystonia [10]. Nevertheless, lesional surgeries still constitute a very crucial part of the armamentarium in the management [11, 12].

This modality of management is particularly important in patients with financial constraints, poor compliance to follow-up visits and those at prone for infections.

Outcomes of surgical interventions in RMDs are less well-known in the literature. There is a dearth of studies on the impact of lesional surgeries and DBS among patients with RMDs. We aimed to discuss our experience over a period of past 15 years on the various surgical interventions performed among patients with RMDs with drug refractory dystonia, tremors, chorea and tics.

METHODS

SUBJECT RECRUITMENT

We performed a retrospective review of all the patients with rare movement disorders who underwent DBS or lesional surgeries from 2006 to 2021 in our institute. A detailed review of all the charts was done. Data were extracted with respect to the diagnoses, duration of symptoms, indications for surgery, medical management tried, the type of surgery performed, pre-operative and post-operative objective assessment and the subsequent long-term outcome. Analyses were performed on the measured clinical scores which included Burke-Fahn-Marsden-Dystonia-Rating Scale (BFMDRS) for dystonia, Fahn-Tolosa-Marin (FTM) scores for tremors, Unified Huntington Disease Rating Scale (UHDRS) for chorea, Yale Global Tic Severity Scale (YGTSS) for tics, Yale-Brown obsessive compulsive severity scale (YBOCSS) for obsessive compulsive symptoms, Hamilton depression rating scale (HDRS) for depression, and Hamilton anxiety rating scale (HARS) for anxiety. Five previously published patients by our centre, three patients of Wilson’s disease (WD), one patient of Neurodegeneration with brain iron accumulation (NBIA) and one patient of Tourette’s syndrome, were also included in the study [13–15]. The Institute Ethics Committee at the National Institute of Mental Health and Neurosciences granted an ethical clearance waiver owing to the retrospective nature of the study with de-identified data being extracted from files, and informed written consent obtained from patients for publication of recorded videos.

STATISTICAL ANALYSIS

Quantitative variables were expressed as frequency and mean ± S.D. Descriptive analyses were done to obtain the
demographic parameters and clinical profile. Repeated-measures ANOVA was used to compare the BFMDRS scores between the independent groups comprising lesioning and DBS as well as overall study population, at baseline, 6-months and 12-months post-surgery with post-hoc analysis wherever applicable. Independent samples T-test was applied between the two groups, lesional surgery and DBS, at each of the time frames. Surgical outcomes were also compared between the two disease groups, WD and NBIA at 6-months and 12-months post-surgical intervention. These tests were corrected using Bonferroni correction. Statistical analyses were applied only on patients with dystonia. A p-value of less than 0.05 was taken as statistically significant. Statistics were performed using IBM SPSS version 23. Graphpad Prism 8 was used for synthesis of figures.

RESULTS

Seventeen patients (11 males, 64.7%) were included in the study (Table 1). The mean age at onset was 13.7 ± 8.9 years with the mean duration of illness prior to the surgery of 5.9 ± 3.7 years. The mean age at the time of the surgery was 19.8 ± 9.7 years, with a range of 6 years to 32 years. The most common underlying etiology was WD (8 patients, 47.1%) followed by NBIA (5 patients, 29.4%), and the predominant phenomenology at the time of surgeries was dystonia in 11 patients (64.7%) and tremor in 5 patients (29.4%). Among patients with dystonia, 6-month follow-up data of BFMDRS motor severity scores were available in all and 12-month follow-up scores were available for 9 patients. Lack of data of these two patients was attributable to the unfortunate demise of one patient of WD from hepatic failure and the absence of follow-up of the patient with DYT-TOR1A (Table 1, Figure 1). Genetic testing was performed in 3 cases. Patient DYT1 had previously reported heterozygous 3-bp deletion (c.907_909del) in exon-5 of TOR1A gene, patient NPC had novel homozygous likely pathogenic missense variant (c.2473T > C.p.Trp825His) in exon-16 of NPC1 gene, and patient NAC had novel homozygous pathogenic nonsense variant (c.9477G < > A.p.Trp3159Ter) in exon-72 of VPS13A gene. Clinical vignette is provided for patient NBIA4, WD8, DYT1, and NBIA2 along with videos for patient NBIA4 (Video e1), WD8 (Video e2), and DYT1 (Video e3).

TREATMENT PRIOR TO THE SURGERY

The patients were tried on symptomatic medical therapy which included clonazepam, baclofen, tetrabenazine, trihexyphenidyl and decoppering agents for a mean duration of 4.6 ± 2.6 years. In patients with WD, the mean daily dose of D-Penicillamine was 937.5 ± 320.0 mg while for Zinc, it was 632.5 ± 341.6 mg. Among patients with primary and secondary dystonia, the mean daily dosage of trihexyphenidyl, tetrabenazine, baclofen, clonazepam and diazepam were 13.6 ± 5.3 mg, 87.5 ± 19.8 mg, 26.8 ± 13.1 mg, 1.5 ± 0.9 mg and 8.8 ± 1.8 mg respectively. Patients with severely disabling movement disorders and suboptimal response to the maximal therapeutic and tolerated dosage of the drugs were considered for the surgical intervention after a detailed discussion with patient and the caregivers.

SURGICAL INTERVENTION: DEEP BRAIN STIMULATION

Nine patients (52.9%) underwent DBS with the mean duration of illness prior to DBS of 4.8 ± 1.8 years (Tables 1, 2). Seven patients (77.8%) underwent DBS for dystonia with underlying etiology of NBIA spectrum disorders in three patients (33.3%), WD in two patients (22.2%), and Niemann-Pick Type C (NPC) and DYT-TOR1A in one patient each (11.1%). Other indications were chorea due to Neuroacanthocytosis in one patient and complex motor and vocal tics in Tourette syndrome in one patient. All these patients underwent bilateral Globus Pallidus interna (GPI) DBS.

SURGICAL INTERVENTION: LESIONAL SURGERIES

Eight patients (47.1%) underwent lesioning surgery after a mean duration of illness of 6.5 ± 5.2 years prior to surgery. The primary indication was tremor in four patients (57.1%), all of whom had WD (n = 4). Three patients with dystonia (37.5%), two with WD and one with NBIA underwent lesioning. A single patient with combined tremor and dystonia who underwent lesioning had NBIA as underlying etiology. Among patients with tremor, three patients underwent unilateral ventralis intermediate nucleus (ViM) thalamotomy (left-2, right-1) whereas one patient underwent bilateral ViM thalamotomy in 2 stages 6-months apart. All patients with dystonia underwent bilateral pallidotomy. The patient with tremor and dystonia (patient NBIA2) underwent left ViM thalamotomy as the tremor was more disabling (Tables 1, 2).

SURGICAL OUTCOMES OF PATIENTS WITH DYSTONIA

Total eleven patients had significant dystonia in our cohort of which ten patients underwent surgeries primarily for dystonia (DBS-7, pallidotomy-3). Irrespective of the type of surgical intervention, statistically significant improvement was noted in the BFMDRS motor scores at 6-months (p < 0.001) and 12-months interval (p = 0.02) compared to the baseline. Lesioning surgery led to a reduction of BFMDRS score by 26.9 ± 19.5% (p = 0.11) at 6 months and 17.4
| VARIABLES (N, % OR MEAN ± S.D) | TOTAL       | LESIONING   | DBS         | REMARKS |
|-------------------------------|-------------|-------------|-------------|---------|
| Number of patients            | 17          | 8           | 9           |         |
| Mean age at onset (y)         | 13.7 ± 8.9  | 13.5 ± 7.2  | 18.8 ± 10.9 |         |
| Mean age at surgery (y)       | 19.8 ± 9.7  | 21.0 ± 8.7  | 19.2 ± 11.6 |         |
| Mean duration of illness before surgery (y) | 5.9 ± 3.7 | 6.5 ± 5.2 | 4.8 ± 1.8 |         |

**Underlying diagnosis**

- Wilson's disease: 8 (47.1%), 6 (75%), 2 (22.2%)
- NBIA spectrum disorder: 5 (29.4%), 2 (25%), 3 (33.3%)
- DYT-TOR1A: 1 (5.9%), 0, 1 (11.1%)
- Neuroacanthocytosis: 1 (5.9%), 0, 1 (11.1%)
- Niemann-Pick disease type C: 1 (5.9%), 0, 1 (11.1%)
- Giles de la Tourette syndrome: 1 (5.9%), 0, 1 (11.1%)

**Indication for surgery**

- Generalized dystonia: 11 (64.7%), 4 (50%), 7 (77.8%)
- Tremors: 5 (29.4%), 5 (62.5%), 0
- Generalized chorea: 1 (5.9%), 0, 1 (11.1%)
- Complex motor tics: 1 (5.9%), 0, 1 (11.1%)

**Type surgery**

- Unilateral ViM thalamotomy: 4 (23.5%), 4 (50%), NA
  (Rt-1, Lt-3)
- Bilateral ViM thalamotomy: 1 (5.9%), 1 (12.5%), NA
- Bilateral pallidotomy: 3 (17.7%), 3 (37.5%), NA
- Bilateral GPi DBS: 9 (52.9%), NA, 9 (100%)

**Complications**

- Speech impairment: 7 (41.2%), 4 (44.4%), 1 (12.5%)
- Swallowing difficulty: 3 (17.7%), 3 (33.3%), 0

**Movement disorder**

- Blepharospasm: 3 (17.7%), 1 (11.1%), 2 (25.0%)
- Status dystonicus: 1 (5.9%), 1 (11.1%), 0
- Persistent dystonia: 5 (29.4%), 2 (22.2%), 3 (37.5%)
- Persistent choreiform movements: 1 (5.9%), 1 (11.1%), 0
- Persistent tremor: 1 (5.9%), 0, 1 (12.5%)
- Persistent tongue dystonia: 2 (11.8%), 0, 2 (25.0%)
- Perioral tightness: 1 (5.9%), 1 (11.1%), 0
- Bradykinesia: 2 (11.8%), 1 (11.1%), 1 (12.5%)
- Parkinsonism: 1 (5.9%), 1 (11.1%), 0
- Gait impairment: 2 (11.8%), 1 (11.1%), 0
- Surgical Site infection: 1 (5.9%), 1 (11.1%), 0

**Dystonia subgroup**

- Pre-operative baseline BFMDRS score: 80.9 ± 20.0, 78.1 ± 26.3, 82.4 ± 17.6, p value 0.75
- BFMDRS score at 6 months post-surgery: 57.8 ± 22.8, 58.3 ± 31.6, 57.4 ± 19.1, p value 0.95
- Percentage reduction of BFDRS score at 6 m: 29.6 ± 16.6, 26.9 ± 19.5 %, 31.6 ± 16.2 %
- BFMDRS mean score difference at baseline and 6 months: p value < 0.001, p value 0.11, p value 0.001
- BFMDRS score at 12 months post-surgery: 60.9 ± 11.1, 57.3 ± 11.2 (n = 3), 62.7 ± 5.8 (n = 6), p value 0.53
- Percentage reduction of BFDRS score at 12 m compared to baseline: 22.3 ± 10.4, 17.4 ± 3.1 %, 24.8 ± 12.1 %
- BFMDRS mean score difference at baseline and 12 months: p value 0.02, p value 0.06, p value 0.010
- BFMDRS mean score difference between 6 m and 12 m: p value 0.28, p value 0.13, p value 0.92

**Table 1** Demographics, clinical profile, surgical interventions and comparison between DBS and lesioning surgery.

@-In one patient, the indication of surgery was tremor and dystonia.

BFMDRS: Burke-Fahn-Marsden-Dystonia-Rating scale, DBS—deep brain stimulation, GPi—globus pallidus interna, Lt—left, m—month, NA—not applicable, Rt—right, ViM—ventralis intermediate nucleus, y—years.
**Figure 1** BMFDRS motor scores at baseline, 6-months and 12-months post operatively in patients with dystonia.

**Video e1** Video of the patient-NBIA4. Segment-1: pre-operative video showing severe generalized dystonia with opisthotonus and Ryle’s tube in situ due to dysphagia. Segment-2: Video of the patient 6-months after bilateral GPI-DBS showing improvement in dystonia, opisthotonus and dysphagia. The video was taken after written informed consent for online publication and dissemination.
Video e2 Video of the patient-WD8. Segment-1: pre-operative video showing significant disabling rubral tremor in right upper limb with conducted tremor in left upper limb as well. Segment-2: 6-months after left ViM thalamotomy showing significant improvement of the tremor and the functional ability. The video was taken after written informed consent for online publication and dissemination.

Video e3 Video of the patient-DYT1. Segment-1: pre-operative video showing significant generalized dystonia. Segment-2: 3-months post bilateral GPi-DBS with significant improvement in generalized dystonia as well as gait. The video was taken after written informed consent for online publication and dissemination.
Table 2 Individual patient characteristics.

# Patient presented at 8 years of age when she only had hepatic manifestations without neurological involvement.

| ID | INDICATION | AAO (YRS) | AAP (YRS) | AAS (YRS) | SEX | MEDICAL MANAGEMENT | SX TYPE | OUTCOME | COMPLICATIONS | STIMULATION PARAMETERS | MANAGEMENT IN FOLLOW UP | OUTCOME |
|----|-------------|-----------|-----------|-----------|-----|--------------------|---------|---------|--------------|------------------------|------------------------|---------|
| WD1| Dystonia    | 8         | 8         | 11        | 3   | F                  | Penicillamine 1 gm THP 6 mg Zinc sulfate 220 mg Baclofen 20 mg | BL GPi Px | No improvement (BFMDRS scores remained unchanged at 6 months) | Expired from hepatic failure | NA | ----- |
| WD2| Dystonia    | 15.5      | 16        | 17        | 1.5 | M                  | Penicillamine 1 gm THP 18 mg Zinc sulfaate 660 mg TBZ 100 mg CBZ 400 mg Baclofen 20 mg | BL GPi Px | Improvement of BFMDRS scores by 40.9% at 6 months and 13.9% at 12 months | Persistent disabling dystonia, blepharospasm, tongue dystonia | NA | Redo bilateral pallidotomy at 14 months post-surgery. Medical management with Penicillamine 1 gm, THP 18 mg, Zinc sulphate 660 mg, TBZ 75 mg, Baclofen 10 mg and CBZ 400 mg | Blepharospasm improved; Dystonia not improved |
| WD3| Dystonia    | 11.5      | 12        | 15        | 3.5 | M                  | Penicillamine 1.25 gm THP 18 mg Zinc sulfaate 220 mg Baclofen 20 mg Clonazepam 1 mg Levodopa 250 mg | BL GPi DBS | Improvement of BFMDRS scores by 16.6% at 6 months and 12.5% at 12 months | Persistent swallowing difficulty at 1 month. Perioral tightness | At 2 months C+/2-1 V/ 150 µS/ 180 Hz C+/9-1 V/150 µS/ 180 Hz | Reprogramming Penicillamine 1.25 gm THP 18 mg Zinc sulphate 220 mg Baclofen 20 mg Clonazepam 1 mg Levodopa 250 mg | Perioral tightness improved; dystonia persisted of lesser severity |
| WD4| Dystonia    | 11        | 12        | 15        | 4   | M                  | Penicillamine 1 gm Zinc sulfaate 660 mg THP 12 mg TBZ 75 mg Levodopa 300 mg Baclofen 20 mg Diazepam 7.5 mg | BL GPi DBS | Improvement of BFMDRS scores by 20% at 6 months and 10% at 12 months | Dystonic spasms | At 3 months C+2-2 V/ 150 µS/ 180 Hz C+10-1 V/150 µS/ 180 Hz | At 1 year follow up, reprogramming to C+2-3 V/ 150 µS/ 180 Hz | Improvement in frequency of dystonic spasms, dystonia persistent |
| ID  | INDICATION    | AAO (YRS) | AAP (YRS) | AAS (YRS) | DOI (YRS) | SEX | MEDICAL MANAGEMENT               | SX TYPE | OUTCOME                                        | COMPLICATIONS                  | STIMULATION PARAMETERS | MANAGEMENT IN FOLLOW UP               | OUTCOME                       |
|-----|---------------|-----------|-----------|-----------|-----------|-----|----------------------------------|---------|------------------------------------|-----------------------------|------------------------|----------------------------------|-------------------------------|
| WD5 | Tremor        | 15        | 17        | 23        | 8         | M   | Penicillamine 1.25 gm THP 18 mg Zinc sulfate 660 mg Baclofen 20 mg | BL VIM Tx | Tremor scores (FTMRS) improved by 87.5% at 5 years and 90.6% at last follow up (10 years) compared to baseline | Dysarthria, postural tremors, bradykinesia persisted. Worsening of tremors to baseline scores | NA                     | Bilateral redo thalamotomy after 6 months At 1 year follow up, Penicillamine 1 gm THP 12 mg Zinc sulfate 660 mg Baclofen 20 mg | Sustained improvement with mild dysarthria and tremors. Functionally independent |
| WD6 | Tremor        | 11        | 8*        | 28        | 17        | F   | Zinc 1320 mg Penicillamine 250 mg Pimozide 250 mg | UL VIM Tx | Tremor scores (FTMRS) improved by 75.9% at 2 months | Mild gait ataxia                  | NA                     | At 2 years follow up, Amantadine 100 mg Zinc 660 mg Penicillamine 250 mg | Mild ataxia persisted. Tremors improved. |
| WD7 | Tremor        | 27        | 30        | 30        | 3         | M   | Penicillamine 750 mg Zinc sulfate 660 mg THP 6 mg TBZ 75 mg Pimozide 250 mg | UL VIM Tx | FTMRS improved by 82.2% at 5 years and 86.7% at 10 years and 84.4% at 16 years follow-up compared to baseline | Transient gait imbalance, post-operative transient pneumocephalus | NA                     | At 16 years follow up, Penicillamine 750 mg THP 12 mg Zinc sulphate 660 mg | Tremors improved satisfactorily. Mild dysarthria has persisted |
| WD8 | Tremor        | 16        | 20        | 22        | 6         | F   | Penicillamine 1 gm Zinc sulfate 660 mg | UL VIM Tx | FTMRS reduction by 94% at 1 year follow-up | No adverse events reported          | NA                     | At 1 year follow up, Penicillamine 500 mg Zinc sulfate 660 mg Clonazepam 0.75 mg | Significant improvement in tremors |
| NBIA1 | Dystonia      | 3.5       | 5         | 7         | 3.5       | F   | TBZ 75 mg Baclofen 30 mg THP 18 mg | BL GPe Px | Improvement of BFMDRS scores by 25% at 6 months and 18.2% at 12 months | Abnormal tongue protrusions                   | NA                     | At 1 year follow up, TBZ 37.5 mg, THP 18 mg, Clonazepam 0.5 mg, Baclofen 30 mg and Haloperidol 5 mg and Inj Botulinum toxin therapy in the tongue | Improvement in severity of dystonia |

(Contd.)
| ID  | INDICATION  | AAO (YRS) | AAP (YRS) | AAS (YRS) | DOI (YRS) | MEDICAL MANAGEMENT | SX TYPE | OUTCOME | COMPLICATIONS | MANAGEMENT IN FOLLOW UP | OUTCOME |
|-----|-------------|-----------|-----------|-----------|-----------|--------------------|---------|---------|---------------|-----------------------|---------|
| NBIA2 | Tremor + Dystonia | 13 | 30 | 30 | 17 | M | Baclofen 30 mg THP 18 mg | UL VM Tx | Improvement of BFMDRS scores by 41.6% at 6 months and 20% at 12 months. FTMRS improvement by 77.8% at 3 years follow-up. | Febrile illness due to chest infection. Worsening of dystonia after stopping haloperidol | At 3 years follow up, Botex for lingual dystonia Baclofen 20 mg THP 12 mg | Required ICU care and tracheostomy. Dystonia persisted with significant disability. Tremors improved. |
| NBIA3 | Dystonia | 7 | 9 | 12 | 5 | M | Baclofen 60 mg Levodopa 400 mg TBZ 112.5 mg THP 12 mg Diazepam 10 mg | BL GPI DBS | Improvement of BFMDRS scores by 27.3% at 6 months and 20.5% at 12 months | Improvement in dystonia score | At 3 months C+1-/1.0 V/150 μsec/130 Hz C+9-/1.0 V/150 μsec/130 Hz | At 2 years follow up, reprogramming C+1-/2.0 V/150 μsec/130 Hz C+9-/1.0 V/150 μsec/130 Hz Baclofen 30 mg Levodopa 400 mg TBZ 75 mg THP 12 mg | Persistent dystonia of reduced severity |
| NBIA4 | Dystonia | 3 | 4 | 6 | 3 | F | THP 19.5 mg Clonazepam 0.75 mg Pimozide 4 mg TBZ 75 mg Baclofen 15 mg | BL GPI DBS | Improvement of BFMDRS scores by 30.4% at 6 months and 35.9% at 12 months | Surgical site infection of cranial and abdominal wound (MRSA). Persistence of morning and nocturnal dystonic spasms | At 3 months, C+1-/3 V/120 μS/160 Hz C+9-/3 V/120 μS/160 Hz | Removal of leads | Improvement of dystonia for next 2 years, re-implantation of DBS leads for worsened dystonia, later expired from chest infection |
| NBIA5 | Dystonia | 26 | 28 | 32 | 6 | M | Baclofen 20 mg TBZ 75 mg Clonazepam 1 mg Levodopa 300 mg | BL GPI DBS | Improvement of BFMDRS scores by 38.0% at 6 months and 32.1% at 12 months | Blepharospasm, Parkinsonism | At 3 months C+1/-2.5 V/210 μS/60 Hz C+5/-2.5 V/210 μS/60 Hz | At 2 years follow up, reprogramming to C+1/-3.5 V/210 μS/130 Hz C+5/-3.4 V/210 μS/130 Hz Botulinum Toxin and medical management with Baclofen 20 mg TBZ 75 mg Clonazepam 0.75 mg Levodopa 300 mg | Blepharospasm improved, dystonia persistent of reduced severity |

(Contd.)
| ID  | INDICATION     | AAO (YRS) | AAP (YRS) | AAS (YRS) | DOI (YRS) | SEX | MEDICAL MANAGEMENT     | SX TYPE | OUTCOME                             | COMPLICATIONS                                      | STIMULATION PARAMETERS                  | MANAGEMENT IN FOLLOW UP                   | OUTCOME                                                                 |
|-----|----------------|-----------|-----------|-----------|-----------|-----|------------------------|---------|------------------------------------|-----------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------------------------------------|
| NPC | Dystonia       | 11        | 14        | 20        | 9         | F   | THP 12 mg, Baclofen 40 mg, TBZ 100 mg, Clonazepam 1.5 mg | BL GPI DBS | Improvement of BFMDRS scores by 21.1% at 6 months and 37.6% at 12 months | Dystonia persistent, speech abnormality, swallowing difficulty | At 3 months, C+1/-1.5 V/90 µS/180 Hz C+9/-1.5 V/90 µS/180 Hz | At 2 years follow up, reprogramming to C+1/-3.5 V/120 µS/180 Hz C+9/-3.5 V/120 µS/180 Hz THP 12 mg Baclofen 40 mg TBZ 50 mg Clonazepam 1.5 mg  | Dystonia severity reduced but persistent  |
|     |                |           |           |           |           |     |                        |         |                                    |                                               |                                          |                                           |                                                                         |
| DYT | Dystonia       | 9         | 11        | 13        | 4         | M   | THP 12 mg, TBZ 75 mg, Levodopa 400 mg | BL GPI DBS | Improvement of BFMDRS scores by 64.1% at 6 months | Persistence of dystonia | At 3 months C+1/-1.3 V/150 µS/150 Hz C+9/-1.3 V/150 µS/150 Hz | At 9 months follow up, THP 12 mg TBZ, Levodopa tapered and stopped   | Improvement in severity of dystonia       |
|     |                |           |           |           |           |     |                        |         |                                    |                                               |                                          |                                           |                                                                         |
| NAC | Chorea         | 37        | 38        | 41        | 4         | M   | TBZ 125 mg, CBZ 600 mg, Clonazepam 0.5 mg, Baclofen 20 mg | BL GPI DBS | Improvement in UHDRS scores by 9.1% at 6 months and 20% at 12 months | Head nodding and persistent choreiform movements | At 3 months C+2/-2.4 V/150 µS/180 Hz C+10/-1.9 V/150 µS/180 Hz | At 4 years follow up, reprogramming to C+2/-2.7 V/90 µS/130 Hz C+10/-2.2 V/90 µS/130 Hz TBZ 50 mg, CBZ 600 mg, Clonazepam 0.75 mg and Baclofen 20 mg  | Improvement of head nodding movements and dysarthria |
|     |                |           |           |           |           |     |                        |         |                                    |                                               |                                          |                                           |                                                                         |
| TS  | Complex motor tics | 10        | 11        | 15        | 5         | M   | Haloperidol 15 mg, Risperidone 6 mg, Aripiprazole 20 mg, Clonidine 0.4 mg, Clonazepam 4 mg, Valproate 800 mg, Fluoxetine 20 mg, Tetrabenazine 25 mg, rTMS | BL GPI DBS | Improvement in tic severity scores (YGTSS scores) by 72% | Slight worsening of motor and vocal tics (YGTSS 30/100) at 1 year with psychiatric manifestations like defiant and demanding behaviours | C+1/-1/3.5 V/60 µS/130 Hz C+9/-3.5 V/60 µS/130 Hz C+1/-3.5 V/60 µS/130 Hz | At 3 years follow up, Amisulpiride 300 mg and Clonazepam 1 mg and behavioural therapy | Mild improvement in behavioural symptoms |

Dhar et al. Tremor and Other Hyperkinetic Movements DOI: 10.5334/tohm.693
± 3.1% (p = 0.06) at 12-months. On the contrary, in the DBS subgroup, the score reduction was by 31.6 ± 16.2% (p = 0.001) and 24.8 ± 12.1% (p = 0.010) at 6-months and 12-months interval, respectively. However, there was no statistically significant improvement at 12-months compared to the 6 months scores in either subgroup. When the DBS and lesioning groups were compared with each other, there was no significant difference either in the baseline (p = 0.75), or in the 6-months (p = 0.95) and 12-months follow-up scores (p = 0.53). There was no significant difference either when 6-months and 12-months outcome was compared between WD and NBIA spectrum subgroups (p = 0.18). Comparison between GPi DBS and bilateral pallidotomy showed no significant difference in mean BFMDRS motor scores at baseline (p = 0.66), 6 months (p = 0.93) or 12 months follow-up period (p = 0.48). Pairwise comparison on average BFMDRS scores, using two-way repeated measures ANOVA with Bonferroni correction, across the timepoints between GPi DBS and pallidotomy revealed a trend favouring DBS even though statistically not significant (p = 0.06) (Tables 1, 2, Figures 1 and 2).

**SURGICAL OUTCOMES OF PATIENTS OTHER THAN DYSTONIA**

Five patients (WD-4, NBIA with tremor and dystonia-1) underwent lesioning surgery for medically refractory tremors. Objective assessment of tremor severity and functional impairment by FTM scores revealed satisfactory response at various time-points after surgery. Mean FTM scores’ reduction at last follow-up, which varied from 6 months to 16 years, was 85.0 ± 7.8%. A single patient with neuroacanthocytosis who underwent DBS for generalized chorea showed minimal improvement in UHDRS score from 36 to 33 (8.3%) at 6-months follow-up and to 30 (16.7%) at 12-months. One patient with Tourette’s syndrome showed remarkable improvement in complex motor and vocal tics by 72% on YGTSS scores at 9-month following bilateral GPi DBS. Additionally, there was reduction in HDRS scores (8/52 to 2/52), and HARS scores (7/56 to 2/56) for depression.
and anxiety respectively. OCD scores (YBOCSS) remained 0 at follow up. This patient was tried on several drugs for varying intervals up to four years and repetitive transcranial magnetic stimulation (rTMS) before he underwent DBS (Table 2).

**COMPLICATIONS OF SURGERIES**

Speech impairment was the most common adverse event observed in 7 patients, four with DBS (Patient-WD4, NBIA5, NPC and NAC) and three with bilateral pallidotomy (Patient-WD1, WD2 and NBIA1). Two patients (patient-WD1 and NBIA1) developed tongue dystonia while three (Patient-WD2, NBIA2, and NBIA5) developed blepharospasm subsequently treated with botulinum toxin therapy. One patient (Patient-WD3) developed perioral dyskinesia post-operatively. Patient-NBIA3 who had undergone bilateral GPI-DBS developed status dystonicus requiring intensive care in the immediate post-operative period and improved with standard medical management and initiation of DBS after a period of six days. Surgical site infection occurred in one patient (NBIA4, case vignette in supplementary material, Video e1) following bilateral GPI DBS necessitating removal of DBS leads. The infection subsequently subsided with no residual complications and patient continued to have sustained improvement even after lead removal. Transient imbalance was seen in two of the patients. Both these patients also had post-surgical pneumocephalus. (Tables 1, 2).

**LONG TERM FOLLOW-UP**

Among WD, long term follow-up was available for three patients (WD6, 2-years; WD7, 16-years; WD8, 2-years) who had undergone unilateral thalamotomy for tremor and all three had persistent reduction in tremor and were functionally independent. Clinical details of WD8 are provided in supplementary material and Video e2. Among patients with NBIA, long term follow-up was available for four. At 2 years follow up, three of the patients (NBIA2, NBIA3 and NBIA5), continued to have persistent dystonia, and required anti-dystonic medications. All three patients reported initial improvement of dystonia at 6 months which was followed by a gradual worsening. Patient NBIA-2, who also had concomitant tremors, exhibited remarkable improvement in tremors in contrast to his dystonia component. Patient-NBIA4, is discussed in case vignette (Supplementary material, Video e1). A single patient of neuro-acanthocytosis showed minimal improvement in chorea at 4 years follow-up compared to baseline. The patient with Tourette syndrome at 18 months follow-up showed mild worsening of YGTSS scores from 27 at 9 months to 30/100 with mild improvement in behavioural symptoms. The patient of NPC who underwent DBS, showed promising results with significant improvement at one year follow-up from BFMDRS motor score of 109 to 68, initially. However, at her second year of follow-up there was worsening of generalized and orolingual dystonia, to BFMDRS motor scores of 96.

**CASE VIGNETTES**

**Patient NBIA4**

This 4-year-old girl presented with generalized dystonia of one year duration. The clinical presentation of pediatric dystonia, significant bulbar involvement and opisthotonus and MRI brain finding of eye-of-tiger appearance suggested a diagnosis of NBIA-pantothenate kinase-associated neurodegeneration (NBIA-PKAN). She was started on medical management which was escalated to tetrabenazine, trihexyphenidyl, clonazepam over a period of next 3 years. She responded unsatisfactorily to medical management and was subsequently taken for DBS. Her BFMDRS score at presentation was 56 which worsened to 92 pre-operatively. She made significant clinical improvement. Her BFMDRS scores improved to 64 and 59 at 6-months and 12-months follow-up respectively (Video e1). Unfortunately, during the follow-up at 2 years, she developed surgical site infection of the cranial wound which mandated removal of leads and intravenous antibiotics after which the infection was controlled. However, she continued to have beneficial effects probably due to the lesional effect. Thereafter, she was lost to follow up. Later, DBS leads were re-implanted at outside centre. Unfortunately, she passed away following chest infection.

**Patient WD8**

This 20-year-old lady, diagnosed patient of WD on treatment, presented to us with severely disabling and medically refractory tremors of 4 years duration. The patient had FTM score of 82 at presentation which did not improve significantly over next two years despite being on penicillamine, zinc, clonazepam, levodopa-carbidopa and propranolol. Subsequently, she underwent left ViM thalamotomy and had a remarkable improvement (93%) in tremors to a score of 5 at 1 year of follow-up (Video e2).

**Patient DYT1**

A13-year-old boy presented with progressive isolated generalized dystonia of 4-years duration, with the onset from right lower limb. At the time of admission, the patient was severely disabled BFMDRS motor score for dystonia of 64. MRI brain with spine was normal except for scoliosis. Genetic testing revealed a previously reported heterozygous 3-bp deletion (c.907_909del) in exon-5 of TOR1A gene confirming the diagnosis as DYT-TOR1A. Patient was on medical management with tetrabenazine (75 mg/day), trihexyphenidyl (12 mg/day) and levodopa 400 mg but
showed unsatisfactory clinical response over the next one year. Subsequently, he underwent bilateral GPI-DBS. At 6-months follow up, patient reported significant clinical improvement with reduction in BFMDRS scores to 23. Post-surgery tetrabenazine and levodopa was stopped and was maintaining well on trihexyphenidyl 12 mg during last follow up at 9 months (Video e3).

Patient NBIA2
This 30-year-old gentleman, diagnosed case of NBIA, presented with features suggestive of early childhood onset generalized combined dystonia with associated tremors from the age of 13 years. Patient was severely disabled due to medical refractoriness of his symptoms. He was on trihexyphenidyl (18 mg/day) and baclofen (30 mg/day). Examination revealed BFMDRS motor scores of 92.5 and FTM score of 54. Patient underwent left ViM thalamotomy. There was notable improvement in dystonia to BFMDRS score of 54 at 6 months follow up, which however was not sustained as the score dropped off to a score of 74 at 12 months and 84 at 3 years. However, tremors showed a sustained improvement to a score of 12 at 3 years follow up. Post-operatively, patient developed blepharospasm, which subsequently improved. There was no response in his lingual dystonia, hence botulinum toxin was administered, in addition of continuation of medical therapy.

DISCUSSION
In this retrospective chart review, we report a series of patients with RMDs who underwent functional neurosurgery for various medically refractory disabling movement disorders. Dystonia was the most common phenomenological indication with WD being the most common aetiology. Overall, the outcome was modest in both DBS and lesioning groups and was better in the first six months compared to the one year follow up. There was no significant difference in the outcome either with respect to the surgery (DBS versus lesioning) or the aetiology (WD versus NBIA). However, patients with tremor who underwent ViM thalamotomy had excellent and sustained response over long follow up. Speech impairment was the most common post-surgical complication and life-threatening complications were observed in two patients; post-operative status dystonicus requiring intensive care in one patient and infection of DBS lead requiring lead removal in the other.

OUTCOMES BASED ON PHENOMENOLOGY
Generalized dystonia is often a highly disabling syndrome and usually has unsatisfactory response to medications further limited by side effects at the high doses required for control of dystonia. Functional surgical treatment options either in the form of DBS or lesioning surgeries can up to a certain extent fill this therapeutic gap. However, the response may not be uniform and depend on various factors such as the underlying aetiology, duration of illness before surgery, nature of progression, underlying disability, and other associated neurological and systemic features. Whereas primary isolated dystonia, lower preoperative score, early surgery predicted a better outcome, combined and progressive dystonia tend to do worse with DBS [16, 17]. In our report as well, among dystonia, patient with DYT-TOR1A, an isolated dystonia had the maximum improvement. The other patients with dystonia were secondary to WD, NBIA or NPC and had mild to moderate response and often were not sustained at one year follow up.

Even though effective, in some patients, DBS may not be feasible due to lack of accessibility and affordability. In such patients, bilateral pallidotomy can be an effective treatment alternative [18]. In addition, pallidotomy is devoid of hardware related adverse effects and need of long-term programming. However, bulbar adverse effects can be more in pallidotomy. In patients with affordability and accessibility issues, having contraindication to DBS, and in those in whom severity of dystonia outweighs the risk of permanent speech disorders, one may consider pallidotomy. In our cohort, three patients underwent bilateral pallidotomy for dystonia due to affordability issues and had modest response. In line with previous studies, both DBS and pallidotomy had similar overall response in our cohort. However, the sample size was too small [19].

Similarly, thalamotomy can be a good alternative to DBS in patients with medically refractory tremor. Often it is done unilaterally, opposite to the most affected side owing to the increased risk of adverse events with bilateral thalamotomy. All patients underwent ViM thalamotomy for refractory tremor in this study and all had moderate to excellent response that was sustained in the majority. Tremor of various aetiologies respond to thalamotomy with minimal side effects and should be considered in patient having predominantly unilateral tremor or in those not affordable for DBS especially so, when it is the dominant and disabling symptom irrespective of the underlying aetiology [14].

OUTCOME BASED ON AETIOLOGY
Wilson's disease
Prior studies in the field investigating the impact of surgical interventions among patients of WD with medically refractory movement disorder have shown variable results. For instance, in a study on 27 patients of WD, 17 of them reported clinical improvement after stereotactic destruction of ventrolateral nucleus of thalamus and subtalamus (Table 3) [20]. However, five patients died of surgery related
| STUDY                        | STUDY DESIGN | SAMPLE SIZE | STUDY SUBJECT(S)                                                                 | SURGERY                          | OUTCOMES                                                                                                                                                                                                 | ADVERSE EVENT PROFILE                                                                                                                                 |
|-----------------------------|--------------|-------------|--------------------------------------------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Starikov et al. 2000 [20]   | Case series  | 27          | 16 patients with tremor form, 8 patients with tremor-rigidity form and a single patient with extrapyramidal-cortical form | Stereotaxic surgery of ViM and subthalamus | Significant decrement in hyperkinesia was reported in 17 patients                                                                                                                                         | 5 deaths of which 2 had bleeding in the treatment zones, 1 brainstem bleed and extension of destruction into the internal capsule and hypothalamus                                                                 |
| Sidiropoulos et al. 2013 [21] | Case report  | 1           | Patient of Wilson’s disease with moderate to severe dystonic symptoms           | Bilateral GPi DBS                | At 20 weeks of stimulation, positive impact on caregiver’s burden, especially in regard to hand dexterity, and gait                                                                                     | No adverse events were reported                                                                                                                                                                           |
| Low et al. 2019 [22]        | Case report  | 1           | Patient of Wilson’s disease with tremors and left sided choreo-athetosis. Tremors were dominant | Posterior subthalamic DBS         | In view of dominant tremor and marked atrophy of lentiform nuclei, posterior subthalamic area was chosen. Early tremor suppression was achieved. Dystonia responded after 1 year | No adverse events were reported                                                                                                                                                                           |
| Umemura et al. 2004 [25]    | Case report  | 1           | 36-year-old patient of proven PKAN with generalized dystonia for 28 years      | Bilateral GPi DBS                | Improvement in motor score from 112 to 2.5 out of 120 with sustained benefit at 1 year follow-up                                                                                                         | No adverse events were reported                                                                                                                                                                           |
| Castelnau et al. 2005 [23]  | Case series  | 6           | Patients with genetically confirmed PKAN                                       | Bilateral GPi DBS                | Improvement in painful dystonic spasms and motor scores. Less significant improvement in BFMDRS disability scores. DBS of the subthalamic nucleus was less beneficial in 3 patients with PKAN compared to the pallidal or thalamic stimulation | No adverse events were reported                                                                                                                                                                           |
| Krause et al. 2006 [19]     | Case report  | 1           | 13-year-old genetically proven patient of PKAN, intractable dystonia for 7 years | Bilateral GPi DBS                | Improvement in motor scores by 70 % in 1 year. Over the next 5 years, there was gradual deterioration, but there was still functionally meaningful benefit | Fixed posturing and bradykinesia worsened                                                                                                                                                             |

(Contd.)
| STUDY            | STUDY DESIGN | SAMPLE SIZE | STUDY SUBJECT(S)                                                                 | SURGERY   | OUTCOMES                                                                                                           | ADVERSE EVENT PROFILE                     |
|------------------|--------------|-------------|----------------------------------------------------------------------------------|-----------|---------------------------------------------------------------------------------------------------------------------|-------------------------------------------|
| Shields et al.  | Case report  | 1           | 18-year-old with genetically proven patient of PKAN with dystonia for 9 years    | Bilateral GPI DBS | Improvement in motor scores on BFMDRS – 86 to 66 out of 120. Patient was able to ambulate post-surgery                | No adverse events reported                |
| Mikati et al.    | Case report  | 1           | 11-year-old girl with early onset genetically proven PKAN                        | Bilateral GPI DBS | Marked improvement in motor and functional scores. Device infection at 3 months led to its removal, following which her motor symptoms and functionality worsened. | Patient returned to pre-surgical state in 4 months |
| Sathe et al.     | Case report  | 1           | 10-year-old girl with PKAN with severe generalized dystonia, with blepharospasm and in a wheel-chair bound state | Bilateral GPI DBS | Sustained improvement in BFMDRS score for 120/120 to 42.5/120 post-operatively at 15 months follow up               | No improvement in speech                  |
| Shin et al. 2011 | Case report  | 1           | 39-year-old lady of genetically proven ChAc with refractory hyperkinetic movement and truncal bending spasm for 4 years duration | Bilateral GPI DBS | Improvement in symptoms which sustained at 13 months                                                               | No adverse events reported                |
| Li et al. 2012   | Case report  | 2           | 2 patients (39 and 30-years of age) with genetically proven ChAc of 22 and 12 years duration respectively | Bilateral GPI DBS | Chorea improved markedly 4 weeks post-stimulation. Dystonia showed only mild improvement                            | No adverse events reported                |
| Ruiz et al. 2009 | Case report  | 1           | 35-year-old of proven ChAc with oromandibular dystonia, dysarthria with chorea    | Bilateral GPI DBS | Improvement in chorea and dystonia                                                                                  | Worsening of truncal spasms              |
| Wihl et al. 2001 | Case report  | 1           | 38-year-old male of proven ChAc with chorea, oromandibular dyskinesia and falls   | Bilateral GPI DBS | No benefits on low or high frequency stimulation                                                                  | No adverse events reported                |
| Burbaud et al.   | Case report  | 1           | 35-year, lady of proven ChAc with chorea, oromandibular dyskinesia, truncal spasm | Bilateral GPI DBS | Improvement in choreic movements on high frequency stimulation (130 Hz)                                             | No adverse events reported                |

Choreacanthocytosis

| Shin et al. 2011 | Case report  | 1           | 39-year-old lady of genetically proven ChAc with refractory hyperkinetic movement and truncal bending spasm for 4 years duration | Bilateral GPI DBS | Improvement in symptoms which sustained at 13 months                                                               | No adverse events reported                |
| Li et al. 2012   | Case report  | 2           | 2 patients (39 and 30-years of age) with genetically proven ChAc of 22 and 12 years duration respectively | Bilateral GPI DBS | Chorea improved markedly 4 weeks post-stimulation. Dystonia showed only mild improvement                            | No adverse events reported                |
| Ruiz et al. 2009 | Case report  | 1           | 35-year-old of proven ChAc with oromandibular dystonia, dysarthria with chorea    | Bilateral GPI DBS | Improvement in chorea and dystonia                                                                                  | Worsening of truncal spasms              |
| Wihl et al. 2001 | Case report  | 1           | 38-year-old male of proven ChAc with chorea, oromandibular dyskinesia and falls   | Bilateral GPI DBS | No benefits on low or high frequency stimulation                                                                  | No adverse events reported                |
| Burbaud et al.   | Case report  | 1           | 35-year, lady of proven ChAc with chorea, oromandibular dyskinesia, truncal spasm | Bilateral GPI DBS | Improvement in choreic movements on high frequency stimulation (130 Hz)                                             | No adverse events reported                |

(Contd.)
| STUDY                          | STUDY DESIGN                      | SAMPLE SIZE | STUDY SUBJECT(S)                                                                 | SURGERY                | OUTCOMES                                                                 | ADVERSE EVENT PROFILE                                                                 |
|-------------------------------|-----------------------------------|-------------|----------------------------------------------------------------------------------|------------------------|--------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| **Rare inherited dystonia**   |                                   |             | Patients with genetically proven RMDs of 1 case each of ataxia-telangiectasia,     | Bilateral GPi DBS      | DBS effects on dystonia severity were marginally effective, with          | Device-related infection occurred in 1 patient (X trisomy). Two patients required a    |
| Beaulieu-Boire et al. 2016    | Prospective                       | 11 patients with genetically proven RMD with disabling dystonia | chorea-atacrocytosis,  | 5                     | a mean improvement of 7.9% ($p = 0.39$) at 1-year follow-up and 16.7%    | second procedure: the patient with SCA 2 received bilateral STN DBS due to lack of     |
|                               |                                   |             | dopa-responsive dystonia, congenital nemalinsmyopathy, methylmalonic aciduria,      |                        | ($p = 0.46$) at last follow-up (mean 47.3 ± 19.9 months after surgery).   | benefit from GPi DBS, with no further improvement, and the patient with SCA 3 had    |
|                               |                                   |             | neuronal ceroid lipofuscinosis, spinocerebellar ataxia types 2 and 3, Wilson's    |                        |                                                                          | repositioning of the electrodes within the GPi, with mild benefit. Deterioration of    |
|                               |                                   |             | disease, Woodhouse–Sokati syndrome, methylmalonic aciduria, and X trisomy          |                        |                                                                          | speech was reported by 2 patients.                                                    |
|                               |                                   |             |                                                                                   |                        |                                                                          |                                                                                       |
| **Primary dystonia**          |                                   |             | Patients with genetically proven RMDs of 1 case each of ataxia-telangiectasia,     | Bilateral GPi DBS      | Improvement in mean movement score ($p < 0.001$). All movement symptoms  | Dysarthria was the most common. 22 adverse events in 19 patients.                       |
| Kupsch et al. 2006 [65]       | Randomized, double-blind, sham-  | 40 patients  | chorea-atacrocytosis, dopa-responsive dystonia, congenital nemalinsmyopathy,     |                        | showed significant improvement except speech and swallowing               |                                                                                       |
|                               | controlled trial                   | of primary generalized or segmental dystonia | methylmalonic aciduria, neuronal ceroid lipofuscinosis, spinocerebellar ataxia   |                        |                                                                          |                                                                                       |
|                               |                                   |             | types 2 and 3, Wilson's disease, Woodhouse–Sokati syndrome, methylmalonic aciduria, |                        |                                                                          |                                                                                       |
|                               |                                   |             | and X trisomy                                                                     |                        |                                                                          |                                                                                       |
|                               |                                   |             |                                                                                   |                        |                                                                          |                                                                                       |
| Vidailhet et al. 2005 [39]    | Prospective, controlled, multi-   | 22 patients | Primary generalized dystonia with a combination of segmental crural dystonia      | Bilateral GPi DBS      | Significant improvement in mean motor ($p < 0.001$) and disability        | 5 transient adverse events in 3 patients                                                |
|                               | centre                             | with primary generalized dystonia | involving one leg and the trunk and the involvement of any other segment (the  |                        | scores at 12 months ($p < 0.001$)                                         |                                                                                       |
|                               |                                   |             | cranium, neck, or upper or lower limbs); no secondary cause, with normal          |                        |                                                                          |                                                                                       |
|                               |                                   |             | neurological examination (except dystonia), MMSE score of at least 24 and normal    |                        |                                                                          |                                                                                       |
|                               |                                   |             | MRI.                                                                                 |                        |                                                                          |                                                                                       |
| Eltahawy et al. 2003 [40]     | Prospective study                 | 15 patients | 9 patients with primary dystonia and 6 patients with secondary dystonia           | Bilateral GPi DBS (except for 3 cases) | Primary dystonia responded better to GPi procedures (DBS and lesioning). | 2 /15 patients, both treated with bilateral pallidotomy, developed persistent speech  |
|                               |                                   | with primary dystonia                  | (2 post encephalitis cases and 1 case each of post stroke, Huntington disease,    |                        | No difference in response between pallidotomy and DBS                       | impairment: hypophonia ($n = 1$) or dysphonia ($n = 1$).                               |
|                               |                                   |             | Tardive dyskinesia and Glutaric aciduria)                                           |                        |                                                                          |                                                                                       |
|                               |                                   |             |                                                                                   |                        |                                                                          |                                                                                       |
| Volkman et al. 2012 [44]      | Randomised control trial          | 40 patients | 40 patients with severe generalised or segmental idiopathic dystasia              | Bilateral GPi DBS      | Significant improvements in dystonia severity at 3-years and 5-years      | Dysarthria and transient worsening of dystonia were the most common non-serious adverse|
|                               |                                   | with primary dystonia                  |                                                                       |                        | compared with baseline were reported                                        | events. 16/21 serious adverse events were device related.                              |
improvements at low frequency stimulation (40 Hz) of GPI-DBS [31]. On the contrary, improvement in dystonia and chorea were exhibited on high frequency stimulation in other case reports, whereas in another report there was no clinically significant outcome [32–34]. Our experience with single patient revealed persistence of choreiform movements although of reduced severity at 4 year follow up.

Primary dystonia
Beneficial effects of DBS in cases of primary dystonia is evident based on various studies [35–41]. Long term experience with DBS has been satisfactory as shown in a limited number of studies till date, not only with respect to motor benefits but also in terms of disability and safety profile [42–44]. Significant improvement of 39–47% in the DBS group in comparison to the sham group (5–22%) was demonstrated in a 3-month randomised controlled trial of pallidal DBS in primary dystonia [45]. The current study showed remarkable benefits at 9 months follow up after bilateral GPI DBS in a single case of TOR1A mutation associated primary dystonia, re-emphasising the evidence based literature.

Tourette syndrome
While grey areas are still persistent with regards to the role of surgical intervention in medically refractory Tourette's syndrome, results from a randomised cross-over trial have been promising with significant improvement in YGTSS scores post DBS [46–47]. The results from the multinational study on medically refractory tic disorder among patients with Tourette syndrome by the International Deep Brain Stimulation Database and Registry showed significant symptomatic improvement after DBS implantation (from mean YGTSS of 70.01 at baseline to 41.19 at 1-year follow-up) [48]. The common sites for implantation of electrodes were chosen as centro-medial region of Thalamus followed by anterior and posterior GPI, and anterior limb of internal capsule [48]. However, the data didn’t reveal any significant difference in clinical outcomes depending on location of stimulation at 1-year follow-up. Other studies have also corroborated the positive impact of DBS on the tic severity scales amongst these patients [49]. Our experience with a single patient has shown significant initial improvement but there was relapse of motor symptoms at 1 year and mild improvement in behavioural symptoms at 3 years follow up.

COMPLICATIONS OF SURGERY
Complications of DBS can be operation, hardware or stimulation related [50]. While there were no intra-operative complications in our study, one of the patients who had undergone DBS suffered from surgical site infection which mandated surgical removal of leads. Among post-operative
complications, speech impairment was the single most common complication. A recent meta-analysis showed a significant risk of speech and language related adverse effects following thalamotomy amounting to 10.3% in the unilateral dystonia subgroup which increased to 56.3% in the bilateral dystonia group [51]. The same study estimated the risk of stimulation induced dysarthria after thalamic DBS to be 24.2% with unilateral procedures and 39.2% with bilateral procedures. Status dystonicus post DBS was reported in a single patient. Although a rare complication, there are scanty reports of the same developing after an uneventful DBS surgery [52]. While sudden failure of DBS device is one of the mechanisms, it has been postulated that just like any other surgery, DBS itself can act as a trigger for worsening dystonia [53]. Blepharospasm and apraxia of eyelid opening are other known complications with DBS, which were also reported by some of our patients [54].

LIMITATIONS
The present study has some obvious limitations such as retrospective nature, small study population, heterogenous study group, lack of a control group and non-blinded assessment. In the context of small sample size, the tests of statistical significance should be interpreted with caution. However, the rarity of such disorders and the phenotypic heterogeneity in each of them is a challenge and makes it difficult to plan a large controlled study. The present study is an attempt to report our experience and the outcome of functional neurosurgery in various rare movement disorders in order to add to the existing knowledge and to benefit the future patients.

CONCLUSION
To conclude, when optimal medical therapy fails to provide a reasonable improvement in the quality of life, functional neurosurgery can be considered on a case-to-case basis. Even though the overall response is significant compared to the baseline, it is often modest and temporary. However, in patients with predominant tremor, primary dystonia, and Tourette syndrome, an excellent and lasting response can be expected and surgery should be contemplated in such cases. It is important to counsel regarding the realistic expectations of benefits and risks associated before going ahead with surgery. Management of rare movement disorders pose a significant challenge due to the rarity of the disorder, dearth of published evidence and practical limitations to perform a planned systematic trial. In this background, it is important to report such cases irrespective of the nature of the outcome to improve the overall understanding. It will help in future, in better patient selection, avoiding unnecessary invasive procedures, provide a realistic expectation and to plan a better and appropriate target. A worldwide registry of patient who have undergone functional neurosurgery for various rare movement disorder may be a right step forward in this regard.

ABBREVIATION
BFMDRS Burke-Fahn-Marsden-Dystonia-Rating Scale
DBS Deep brain stimulation
ERN European Reference Network
FTM Fahn-Tolosa-Marin
GPI Globus pallidus interna
HARS Hamilton anxiety rating scale
HDRS Hamilton depression rating scale
MRI Magnetic resonance imaging
NBIA Neurodegeneration with brain iron accumulation
NPC Niemann-Pick type C
PKAN Pantothenate kinase-associated neurodegeneration
RD Rare disease
RMDs Rare movement disorders
RND Rare neurologic disease
rTMS Repetitive transcranial magnetic stimulation
S.D. Standard deviation
UHDRS Unified Huntington Disease Rating Scale
ViM Ventralis intermediate nucleus
WD Wilson’s disease
YBOCSS Yale-Brown obsessive compulsive severity scale
YGTSS Yale Global Tic Severity Scale

ETHICS AND CONSENT
The authors confirm that the approval of an Institutional Review Board was not required for this work. Informed written consent was obtained from the patient. We confirm that we have read the journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

COMPETING INTERESTS
The authors have no competing interests to declare.

AUTHOR CONTRIBUTIONS
Debjyoti Dhar and Vikram Venkappayya Holla contributed equally.
AUTHOR AFFILIATIONS

Debjyoti Dhar, MBBS orcid.org/0000-0002-4835-4698
Department of Neurology, National institute of Mental Health and Neurosciences (NIMHANS, India – 560029), IN

Pramod Kumar Pal, MD, DNB, DM orcid.org/0000-0002-3634-2219
Department of Neurology, National institute of Mental Health and Neurosciences (NIMHANS, India – 560029), IN

Vikram Venkappaya Holla, MD, DM orcid.org/0000-0002-7933-8826
Department of Neurology, National institute of Mental Health and Neurosciences (NIMHANS, India – 560029), IN

Nitin Kamble, MD, DM
Department of Neurosurgery, National institute of Mental Health and Neurosciences (NIMHANS, India – 560029), IN

Ravi Yadav, MD, DM orcid.org/0000-0002-8016-9089
Department of Neurology, National institute of Mental Health and Neurosciences (NIMHANS, India – 560029), IN

Dwarakanath Srinivasas, MS, MCh orcid.org/0000-0001-7330-0627
Neurosurgery, National institute of Mental Health and Neurosciences (NIMHANS, India – 560029), IN

REFERENCES

1. Gammie T, Lu CY, Babar ZU. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. PLoS One. 2015; 10(10): e0140002. DOI: https://doi.org/10.1371/journal.pone.0140002

2. Reinhard C, Bouchoud-Lévi AC, Bäumer T, Bertini E, Brunelle A, Buizer AI, et al. The European Reference Network for Rare Neurological Diseases. Front Neurol. 2021 January; 11: 1–7. DOI: https://doi.org/10.3389/fneur.2020.616569

3. Kluger BM, Klepitskaya O, Okun MS. Surgical treatment of movement disorders. Neural Clin 2009; 27(3): 633–677, v. DOI: https://doi.org/10.1016/j.ncl.2009.04.006

4. Moro E, LeReun C, Krauss JK, et al. Efficacy of pallidal stimulation in isolated dystonia: a systematic review and meta-analysis. Eur J Neural. 2017; 24(4): 552–560. DOI: https://doi.org/10.1111/ene.13255

5. Holloway KL, Baron MS, Brown R, Cifu DX, Carne W, Ramakrishnan V. Deep brain stimulation for dystonia: a meta-analysis. Neuromodulation. 2006; 9(4): 253–261. DOI: https://doi.org/10.1111/j.1525-1403.2006.00067.x

6. Ruge D, Cif L, Limousin P, et al. Shaping reversibility? Long-term deep brain stimulation in dystonia: the relationship between effects on electrophysiology and clinical symptoms. Brain. 2011; 134( Pt 7): 2106–2115. DOI: https://doi.org/10.1093/brain/awr122

7. Cif L, Vasques X, Gonzalez V, et al. Long-term follow-up of DYT1 dystonia patients treated by deep brain stimulation: an open-label study. Mov Disord. 2010; 25(3): 289–299. DOI: https://doi.org/10.1002/mds.22802

8. Becerra JE, Zorro O, Ruiz-Gavirio R, Castañeda-Cordona C, Otálora-Esteban M, Henao S, Navarrete S, Acevedo JC, Rosselli D. Economic Analysis of Deep Brain Stimulation in Parkinson Disease: Systematic Review of the Literature. World Neurosurg. 2016 Sep; 93: 44–9. DOI: https://doi.org/10.1016/j.wneu.2016.05.028

9. Dang TTH, Rowell D, Connelly LB. Cost-Effectiveness of Deep Brain Stimulation With Movement Disorders: A Systematic Review. Mov Disord Clin Pract. 2019 May 17; 6(5): 348–358. DOI: https://doi.org/10.1002/mdc3.12780

10. Diamond A, Jankovic J. The effect of deep brain stimulation on quality of life in movement disorders. Journal of Neurology, Neurosurgery & Psychiatry. 2005; 76: 1188–1193. DOI: https://doi.org/10.1136/jnnp.2005.065334

11. Lozano AM, Kumar R, Gross RE, et al. Globus pallidus internus pallidotomy for generalized dystonia. Mov Disord. 1997; 12(6): 865–870. DOI: https://doi.org/10.1002/mds.87012060

12. Garg K, Samala R, Agrawal M, Rajan R, Singh M. Pallidotomy for Dystonia. Neurol India. 2020; 68(Supplement): S322–S324. DOI: https://doi.org/10.4103/0028-3886.302460

13. Pal PK, Sinha S, Pillai S, Taly AB, Abraham RG. Successful treatment of tremor in Wilson’s disease by thalamotomy: A case report. Mov Disord. 2007; 22(15): 2287–2290. DOI: https://doi.org/10.1002/mds.21750

14. Dwarakanath S, Zafar A, Yadav R, et al. Does lesioning surgery have a role in the management of multietiological tremor in the era of Deep Brain Stimulation? Clin Neurol Neurosurg. 2014; 125: 131–136. DOI: https://doi.org/10.1016/j.clineuro.2014.07.016

15. Dwarakanath S, Hegde A, Ketan J, et al. “I swear, I can’t stop it!” – A case of severe Tourette’s syndrome treated with deep brain stimulation of anteromedial globus pallidus interna. Neurol India. 2017; 65(1): 99–102. DOI: https://doi.org/10.4103/0028-3886.198188

16. Chen W, Fan H, Lu G. The Efficacy and Predictors of Using GPI-DBS to Treat Early-Onset Dystonia: An Individual Patient Analysis. Neural plasticity. 2021. DOI: https://doi.org/10.1155/2021/9924639

17. Beaulieu-Boire I, Aquino CC, Fasano A, et al. Deep Brain Stimulation in Rare Inherited Dystonias. Brain Stimul. 2016; 9(6): 905–910. DOI: https://doi.org/10.1016/j.brs.2016.07.009

18. Centen LM, Oterdoom DLM, Tijssen MAJ, Lesman-Leegte I, van Egmond ME, van Dijk JMC. Bilateral Pallidotomy for Dystonia: A Systematic Review. Mov Disord. 2021; 36(3): 547–557. DOI: https://doi.org/10.1002/mds.28384

19. Gross RE. What happened to posterovernal pallidotomy for Parkinson’s disease and dystonia? Neurotherapeutics. 2008; 5(2): 281–293. DOI: https://doi.org/10.1016/j.nurt.2008.02.001

20. Starikov AS. Electrical stimulation of the brain in Wilson-Konovalov hepatocerebral dystrophy (a neuromorphological
and neurophysiological analysis). *Neurosci Behav Physiol.* 2002; 32(3): 255–257. DOI: https://doi.org/10.1023/A:1015006206272

21. Sidiropoulos C, Hutchison W, Mestre T, et al. Bilateral pallidal stimulation for Wilson's disease. *Mov Disord.* 2013; 28(9): 1292–1295. DOI: https://doi.org/10.1002/mds.25446

22. Low HL, Alexander SK, Misbahuddin A, Gillett GT. Posterior subthalamic area deep brain stimulation for treatment of tremor and dystonia in Wilson's disease. *Brain Stimul.* 2019; 12(5): 1304–1306. DOI: https://doi.org/10.1016/j.brs.2019.05.014

23. Castelnau P, Cif L, Valente EM, et al. Pallidal stimulation improves pantothenate kinase-associated neurodegeneration. *Ann Neural.* 2005; 57(5): 738–741. DOI: https://doi.org/10.1022/ana.20457

24. Sathe KP, Hegde AU, Doshi PK. Deep brain stimulation improves quality of life in pantothenate kinase-associated neurodegeneration. *J Pediatr Neurol.* 2013; 8(1): 46–48. DOI: https://doi.org/10.4103/1817-1745.111423

25. Umemura A, Jorgi JL, Dolinskas CA, Stern MB, Baltuch GH. Pallidal deep brain stimulation for longstanding severe generalized dystonia in Hallervorden-Spatz syndrome. *Case report. J Neurosurg.* 2004; 100(4): 706–709. DOI: https://doi.org/10.3171/jns.2004.10.04.0706

26. Shields DC, Sharma N, Gale JT, Eskandar EN. Pallidal stimulation for dystonia in pantothenate kinase-associated neurodegeneration. *Pediatr Neural.* 2007; 37(6): 442–445. DOI: https://doi.org/10.1016/j.pediatrneur.2007.08.006

27. Krause M, Fogel W, Tronnier V, et al. Long-term benefit to pallidal deep brain stimulation in a case of dystonia secondary to pantothenate kinase-associated neurodegeneration. *Mov Disord.* 2006; 21(12): 2255–2257. DOI: https://doi.org/10.1002/mds.21166

28. Mikati MA, Yehya A, Darwish H, Karam P, Comair Y. Deep brain stimulation as a mode of treatment of early onset pantothenate kinase-associated neurodegeneration. *Eur J Paediatr Neurol.* 2009; 13(1): 61–64. DOI: https://doi.org/10.1016/j.ejpn.2008.01.006

29. De Vloo P, Lee DJ, Dallapiazza RF, Rohani M, Fasano A, Munhoz RP, et al. Deep brain stimulation for pantothenate kinase-associated neurodegeneration: A meta-analysis. *Mov Disord.* 2019; 34(2): 264–73. DOI: https://doi.org/10.1002/mds.27563

30. Shin H, Ki CS, Cho AR, et al. Globus pallidus interna deep brain stimulation improves chorea and functional status in a patient with chorea-acanthocytosis. *Stereotact Funct Neurosurg.* 2012; 90(4): 273–277. DOI: https://doi.org/10.1159/000338216

31. Li P, Huang R, Song W, et al. Deep brain stimulation of the globus pallidus interna improves symptoms of chorea-acanthocytosis. *Neurol Sci.* 2012; 33(2): 269–274. DOI: https://doi.org/10.1007/s10072-011-0741-y

32. Ruiz PJ, Ayerbe J, Bader B, et al. Deep brain stimulation in chorea acanthocytosis. *Mov Disord.* 2009; 24(10): 1546–1547. DOI: https://doi.org/10.1002/mds.22592

33. Burbaud P, Rougier A, Ferrer X, et al. Improvement of severe trunk spasms by bilateral high-frequency stimulation of the motor thalamus in a patient with chorea-acanthocytosis. *Mov Disord.* 2002; 17(1): 204–207. DOI: https://doi.org/10.1002/mds.1260

34. Wühl G, Volkmann J, Allert N, Lehrke R, Sturm V, Freund HJ. Deep brain stimulation of the internal pallidum did not improve chorea in a patient with neuro-acanthocytosis. *Mov Disord.* 2001; 16(3): 572–575. DOI: https://doi.org/10.1002/mds.1109

35. Yianni J, Bain P, Giladi N, et al. Globus pallidus internus deep brain stimulation for dystonic conditions: a prospective audit. *Mov Disord.* 2003; 18(4): 436–442. DOI: https://doi.org/10.1002/mds.10380

36. Coubes P, Roubertie A, Vayssiere N, Hemm S, Echenne B. Treatment of DYT1-generalised dystonia by stimulation of the internal globus pallidus. *Lancet.* 2000; 355(9222): 2220–2221. DOI: https://doi.org/10.1016/S0140-6736(00)02410-7

37. Krauss JK, Loher TJ, Weigel RH, Capelle HH, Weber S, Burgunder JM. Chronic stimulation of the globus pallidus internus for treatment of non-dYT1 generalized dystonia and choreatothetosis: 2-year follow up. *J Neurosurg.* 2003; 98(4): 785–792. DOI: https://doi.org/10.3171/jns.2003.98.4.0785

38. Cif L, Coubes P. Historical developments in children's deep brain stimulation. *Eur J Paediatr Neurol.* 2017; 21(1): 109–117. DOI: https://doi.org/10.1016/j.ejpn.2016.08.010

39. Vidaliheit M, Vercueil L, Houeto JL, et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. *N Engl J Med.* 2005; 352(5): 459–467. DOI: https://doi.org/10.1056/NEJMoa042187

40. Eltahawy HA, Saint-Cyr J, Giladi N, Lang AE, Lozano AM, Kelly PJ, et al. Primary Dystonia is More Responsive than Secondary Dystonia to Pallidial Interventions: Outcome after Pallidotomy or Pallidal Deep Brain Stimulation. *Neurosurgery.* 2004; 54(3): 613–21. DOI: https://doi.org/10.1227/01.NEU.0000108643.94730.21

41. Krause P, Volzmann S, Ewert S, Kupsch A, Schneider GH, Kuhn AA. Long-term effects of bilateral pallidal deep brain stimulation in dystonia: a follow-up between 8 and 16 years. *J Neural.* 2020; 267(6): 1622–1631. DOI: https://doi.org/10.1007/s00415-020-09745-z

42. Isaías IU, Alterman RL, Tagliati M. Deep brain stimulation for primary generalized dystonia: long-term outcomes. *Arch Neurol.* 2009; 66(4): 465–470. DOI: https://doi.org/10.1007/s00415-020-09745-z

43. Dinkelbach L, Mueller J, Poewe W, et al. Cognitive outcome of pallidal deep brain stimulation for primary cervical dystonia: One year follow up results of a prospective multicenter trial. *Parkinsonism Relat Disord.* 2015; 21(8): 976–980. DOI: https://doi.org/10.1016/j.parkreldis.2015.06.002
44. Volkmann J, Wolters A, Kupsch A, Müller J, Kühn AA, Schneider GH, et al. Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial. Lancet Neurol. 2012; 11(12): 1029–38. DOI: https://doi.org/10.1016/S1474-4422(12)70257-0

45. Kupsch A, Benecke R, Muller J, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med. 2006; 355(19): 1978–1990. DOI: https://doi.org/10.1056/NEJMo063618

46. Xu W, Zhang C, Deeb W, et al. Deep brain stimulation for Tourette’s syndrome. Translational neurodegeneration. 2020; 9(1): 1–19. DOI: https://doi.org/10.1186/s40035-020-0183-7

47. Kefalopoulos Z, Zrinzo L, Jahanshahi M, et al. Bilateral globus pallidus stimulation for severe Tourette’s syndrome: a double-blind, randomised crossover trial. The Lancet Neurology. 2015; 14(6): 595–605. DOI: https://doi.org/10.1016/S1474-4422(15)00008-3

48. Martinez-Ramirez D, Jimenez-Shahed J, Leckman JF, et al. Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome: The International Tourette Syndrome Deep Brain Stimulation Public Database and Registry. JAMA Neurotol. 2018; 75(3): 353–359. DOI: https://doi.org/10.1001/jamaneurol.2017.4317

49. Casagrande SCB, Cury RG, Alho EJL, Fonoff ET. Deep brain stimulation in Tourette’s syndrome: evidence to date. Neuropsychiatr Dis Treat. 2019; 15: 1061–1075. DOI: https://doi.org/10.2147/NDT.S139368

50. Chan DT, Zhu XL, Yeung JH, et al. Complications of deep brain stimulation: a collective review. Asian J Surg. 2009; 32(4): 258–263. DOI: https://doi.org/10.1016/S1015-9584(09)60404-8

51. Alomar S, King NK, Tam J, Bari AA, Hamani C, Lozano AM. Speech and language adverse effects after thalamotomy and deep brain stimulation in patients with movement disorders: A meta-analysis. Mov Disord. 2017; 32(1): 53–63. DOI: https://doi.org/10.1002/mds.26924

52. Ruiz-Lopez M, Munhoz RP, Kalia SK, Zorzi G, Nardocci N, Fasano A. Status dystonicus induced by deep brain stimulation surgery. Neurology. 2020; 41(3): 729–730. DOI: https://doi.org/10.1007/s10072-019-04083-z

53. Rohani M, Munhoz RP, Shahidi G, Parvaresh M, Miri S. Fatal Status Dystonicus in Tardive Dystonia Due to Depletion of Deep Brain Stimulation’s Pulse Generator. Brain Stimul. 2017; 10(1): 160–161. DOI: https://doi.org/10.1016/j.brs.2016.10.006

54. Baizabal-Carvallo JF, Jankovic J. Movement disorders induced by deep brain stimulation. Parkinsonism Relat Disord. 2016; 25: 1–9. DOI: https://doi.org/10.1016/j.parkreldis.2016.01.014